Clinical Context Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects up to 70-80% of patients with type 2 diabetes and obesity. This combination creates a dangerous metabolic triad: insulin resistance drives hepatic lipogenesis, accumulated liver fat worsens systemic insulin resistance, and chronic hepatic inflammation can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. Despite this enormous burden, no FDA-approved pharmacotherapy specifically targets MASLD, leaving clinicians with limited options beyond weight loss and glycemic control. Curcumin, the principal bioactive compound in turmeric (Curcuma longa), has attracted attention for its anti-inflammatory and antioxidant properties. Mechanistically, curcumin activates AMP-activated protein kinase (AMPK), inhibits…
Author: FWA
Clinical Context The gut microbiome has emerged as a significant player in metabolic health. Patients with type 2 diabetes consistently show altered gut microbial composition (dysbiosis) compared to healthy individuals: reduced microbial diversity, decreased beneficial bacteria like Bifidobacterium and Akkermansia, and increased pro-inflammatory species. Whether this dysbiosis is cause or consequence of metabolic dysfunction remains debated, but accumulating evidence suggests it contributes to insulin resistance through multiple mechanisms. Gut bacteria influence host metabolism through several pathways. Short-chain fatty acid (SCFA) production from fiber fermentation improves insulin sensitivity and stimulates GLP-1 secretion. Intestinal barrier integrity depends on commensal bacteria; a “leaky…
Clinical Context Randomized controlled trials establish efficacy under ideal conditions, but real-world effectiveness may differ due to patient selection, adherence patterns, and clinical heterogeneity. The SUSTAIN and PIONEER programs demonstrated semaglutide’s impressive glycemic and weight effects in carefully selected populations following strict protocols. Whether these benefits translate to routine clinical practice—where patients are less homogeneous, adherence is variable, and comparators reflect actual prescribing patterns—remained an important question. Pragmatic trials bridge this gap by randomizing patients in real-world settings with minimal exclusion criteria and comparing treatments as they’re actually used. This design sacrifices some internal validity for enhanced external validity and…
Clinical Context Type 2 diabetes is paradoxically associated with increased fracture risk despite often-normal or even elevated bone mineral density (BMD). This “diabetes bone paradox” reflects impaired bone quality—changes in microarchitecture, collagen cross-linking, and accumulated advanced glycation end-products (AGEs) that weaken bone independent of BMD. Postmenopausal women with diabetes face compounded risk from both estrogen deficiency and diabetes-related bone fragility. The choice of diabetes medication may influence bone health. Thiazolidinediones (pioglitazone, rosiglitazone) increase fracture risk, particularly in women, through PPAR-gamma activation that shifts bone marrow stromal cells toward adipocyte rather than osteoblast differentiation. SGLT2 inhibitors have raised concerns about potential…
Clinical Context Diabetic foot ulcers (DFUs) affect approximately 15-25% of people with diabetes during their lifetime and are the leading cause of non-traumatic lower limb amputation. Despite advances in wound care, many DFUs remain recalcitrant, with healing rates of only 30-50% at 12 weeks with standard treatment. The impaired healing environment in diabetes—characterized by chronic inflammation, impaired angiogenesis, cellular senescence, and deficient growth factor signaling—creates a hostile wound bed that resists conventional therapies. Mesenchymal stem cells (MSCs) have emerged as promising wound healing agents due to their ability to modulate inflammation, promote angiogenesis, and stimulate tissue regeneration. However, direct cell…
Clinical Context Perioperative hyperglycemia and glucose variability are independent predictors of poor outcomes after cardiac surgery, including increased mortality, sternal wound infection, atrial fibrillation, and prolonged ICU stay. Diabetic patients undergoing coronary artery bypass grafting (CABG) are at particularly high risk: surgical stress triggers counter-regulatory hormone release (cortisol, catecholamines, glucagon) that induces insulin resistance and hyperglycemia even in non-diabetics. In patients with pre-existing diabetes, this stress response amplifies already impaired glucose homeostasis. Managing perioperative glucose is challenging. Insulin infusion protocols attempt to maintain tight control but risk hypoglycemia—itself associated with adverse outcomes. Glucose variability (fluctuations in glucose levels) may be…
Clinical Context Pediatric type 1 diabetes management remains challenging despite advances in technology. While continuous glucose monitoring (CGM) provides unprecedented visibility into glucose patterns, the data alone doesn’t improve outcomes—it’s what patients and families do with the data that matters. Many children and adolescents with type 1 diabetes remain above target, with mean HbA1c levels in pediatric diabetes registries typically ranging from 8.0-9.0%, well above the recommended target of less than 7.0%. The traditional model of quarterly clinic visits leaves families to navigate daily diabetes management largely on their own between appointments. This interval is too long to address the…
Summary: In adults with persistent and recalcitrant diabetic foot ulcers that failed to heal with conventional treatment, full-thickness decellularized placental membrane allograft (FT-DPM) applied to the debrided wound bed for 5-9 days with reapplication as needed demonstrated significantly increased complete wound closure rates and accelerated healing time compared to standard of care alone including wound debridement and moist wound therapy without allograft, with primary adverse events limited to mild to moderate wound site irritation that did not prevent continued treatment. PICO Description Population Adults with persistent and recalcitrant diabetic foot ulcers that failed to heal with conventional treatment. Intervention Full-thickness…
Clinical Context Prediabetes affects approximately 96 million American adults, with global prevalence estimates exceeding 500 million. The condition represents a crucial intervention window: the Diabetes Prevention Program (DPP) demonstrated that intensive lifestyle intervention reduces progression to type 2 diabetes by 58%. However, the original DPP model required 16 in-person sessions over 24 weeks plus monthly follow-up—a resource-intensive approach difficult to scale in primary care. Digital health interventions offer the promise of scalability. Text messaging (SMS) is particularly attractive because it requires no app downloads, works on basic phones, and has near-universal reach. SMS-based programs have shown efficacy for medication adherence,…
Clinical Context Chronic low-grade inflammation is increasingly recognized as a key driver of metabolic disease. In obesity and prediabetes, adipose tissue becomes dysfunctional, secreting pro-inflammatory cytokines (TNF-α, IL-6) while infiltrating macrophages perpetuate inflammation. This inflammatory milieu contributes to insulin resistance, beta-cell dysfunction, and ultimately type 2 diabetes. Elevated CRP and other inflammatory markers predict diabetes development independent of glycemia. Weight loss improves inflammation, but questions remain about whether the method of weight loss matters. Intermittent fasting (IF) and time-restricted eating (TRE) have gained popular attention, with proponents claiming benefits beyond simple calorie reduction—purportedly through effects on circadian biology, autophagy, and…